LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism

Photo by atikahakhtar from unsplash

Symptomatic dermographism (SD, formerly also known as urticaria factitia) is a form of chronic inducible urticaria (CIndU) characterized by chronic itch and the development of itchy wheals upon skin exposure… Click to show full abstract

Symptomatic dermographism (SD, formerly also known as urticaria factitia) is a form of chronic inducible urticaria (CIndU) characterized by chronic itch and the development of itchy wheals upon skin exposure to friction, for example after rubbing or scratching of the skin (1). SD is one of the most common forms of CIndU and can be associated with a high burden and strong quality of life (QoL) impairment, and it often is: In a recent study, in 150 patients with SD, over half of the patients reported disturbed sleep and chronic fatigue, almost half had significantly impaired QoL, and 7% stated that a normal life was not possible for them, with major effects of SD on work, leisure, sports, and social activities and contacts. This article is protected by copyright. All rights reserved.

Keywords: symptomatic dermographism; dermographism; benralizumab treatment; patient chronic; treatment patient; benefit benralizumab

Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.